Next Article in Journal
Derivatization of Abietane Acids by Peptide-like Substituents Leads to Submicromolar Cytotoxicity at NCI-60 Panel
Previous Article in Journal
A Series of Novel 1-H-isoindole-1,3(2H)-dione Derivatives as Acetylcholinesterase and Butyrylcholinesterase Inhibitors: In Silico, Synthesis and In Vitro Studies
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 29
Issue 15
10.3390/molecules29153531
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Brief Report

Changes in the Sensitivity of MCF-7 and MCF-7/DX Breast Cancer Cells to Cytostatic in the Presence of Metformin

by
Justyna Płonka-Czerw
*,
Luiza Żyrek
and
Małgorzata Latocha
Department of Cell Biology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Jedności 8, 41-200 Sosnowiec, Poland
*
Author to whom correspondence should be addressed.
Molecules 2024, 29(15), 3531; https://doi.org/10.3390/molecules29153531
Submission received: 1 July 2024 / Revised: 22 July 2024 / Accepted: 26 July 2024 / Published: 27 July 2024
Browse Figures
Versions Notes

Abstract

:
Multidrug resistance is a serious problem in modern medicine and the reason for the failure of various therapies. A particularly important problem is the occurrence of multidrug resistance in cancer therapies which affects many cancer patients. Observations on the effect of metformin—a well-known hypoglycemic drug used in the treatment of type 2 diabetes—on cancer cells indicate the possibility of an interaction of this substance with drugs already used and, as a result, an increase in the sensitivity of cancer cells to cytostatics. The aim of this study was to evaluate the effect of metformin on the occurrence of multidrug resistance of breast cancer cells. The MCF-7-sensitive cell line and the MCF-7/DX cytostatic-resistant cell line were used for this study. WST-1 and LDH assays were used to evaluate the effects of metformin and doxorubicin on cell proliferation and viability. The effect of metformin on increasing the sensitivity of MCF-7 and MCF-7/DX cells to doxorubicin was evaluated in an MDR test. The participation of metformin in increasing the sensitivity of resistant cells to the effect of the cytostatic (doxorubicin) has been demonstrated.

Graphical Abstract

1. Introduction

Multidrug resistance is one of the most important causes of failures of cancer therapy. This situation is associated with various pharmacological and cellular conditions. These include mutations and deregulations within proteins and enzymes involved in the activation of chemotherapeutic drugs in cells and increased metabolism of xenobiotics or induction of antiapoptotic gene expression. There is also increasing evidence that cancer stem cells (CSCs) are involved in the development of MDR [1]. The most frequently observed changes in cell sensitivity to drugs are connected with the transport of drugs through membranes and cytostatic removal rate from the cell by membrane transport proteins.
Most of the proteins involved in the transport of drugs from the cell to the intracellular space belong to the family of ABC proteins. This type of proteins contains the ATP-binding domain (ATP-binding cassette family). A transport protein associated with drug resistance, but not belonging to the ABC family, is also described. This protein is defined as LRP (lung cancer resistance-related protein) [2]. It is located within the nuclear membrane and its role is probably related to cytostatic removal from the cell nucleus to the cytosol. Resistance to therapy is often associated with the simultaneous overexpression of MRP and LRP or that of MRP, LRP and P-gp [3].
Metformin, a well-known hypoglycemic drug, is mainly used in the treatment of type 2 diabetes. It reduces hepatic glucose production and sensitizes peripheral tissues to insulin. It stimulates the AMPK enzyme (AMP-dependent kinase), which leads to changes in the sensitivity of cells to insulin increases, peripheral glucose uptake and its metabolism in cells. It decreases the absorption of glucose in the gastrointestinal tract, reduces lipogenesis and stimulates the process of β-oxidation. It increases the sensitivity of cells to the action of incretin hormones, i.e., glucose-dependent insulin-like peptide (GIP) and glucagon-like peptide 1 (GLP1) [4]. The beneficial effects of metformin in cancer are related to the inhibition of the mTOR signaling pathway (by activating AMPK). This leads to, e.g., the inhibition of cell proliferation, which means that it can have an impact on inhibiting the growth of cancer cells but also play an important role in the aging processes of organisms [4,5]. The suppression of the mTOR pathway also leads to the induction of autophagy, which is attributed a significant role in the process of extending life. Studies conducted in vitro on cancer cells indicate the possibility of interactions of metformin with drugs already used by sensitizing cells to cytostatics [6,7,8,9,10,11,12].
The aim of this study was to assess the effect of metformin on the occurrence of multidrug resistance. The effect of metformin of breast cancer cells originating from the metastatic focus were analyzed: MCF-7-line human-breast-adenocarcinoma wild-line cells, which are sensitive to cytostatics, and MCF-7/DX human-breast-adenocarcinoma subline cells resistant to cytostatics.

2. Results

The result of the WST test performed for cells of the MCF-7 line after 72 h of incubation showed the toxic effect of metformin at a concentration of 50 mM and 100 mM, and the toxic effect of doxorubicin depending on its concentration in the medium. An increase in the toxic effect of doxorubicin was also observed in the presence of metformin at both 12.5 mM and 50 mM. Under the same experimental conditions, the results obtained for the cells of the MCF-7/DX line indicate a sensitivity of the cells to metformin, with the highest decrease in absorbance at a concentration of 100 mM and doxorubicin (significant decrease in absorbance at 50 µM and 100 µM). Simultaneous exposure of MCF-7/DX to doxorubicin with the addition of metformin—both at a concentration of 12.5 mM and 50 mM—causes a decrease in the relative number of viable cells in the cultures (Figure 1a).
The results of the LDH tests confirm the dependencies obtained in the WST-1 tests and indicate the cytotoxic effect of the abovementioned drugs on cells in cultures (Figure 1b).
The effectiveness of metformin in overcoming the resistance of the tested cells to doxorubicin is shown in Figure 1c. The dye included in the MDR (Sigma-Aldrich, St. Louis, MO, USA) test quickly penetrates through the membrane into the cell. If not removed outside, it undergoes an enzymatic reaction and shows fluorescence. The increase in fluorescence of MCF-7/DX cell cultures exposed to metformin, in the concentration range from 1.56 mM to 50 mM, indicates an increase in the sensitivity of the tested cells to doxorubicin.
Based on the molecular structure of metformin (Figure 2, Table 1), 33 potential targets of metformin were predicted using the SwissTargetPrediction online tool.

3. Discussion

One of the most important reasons for the failure of cancer therapy is the development of congenital or acquired drug resistance to chemotherapeutic agents. In the case of congenital resistance, the cancer cells do not respond to standard chemotherapeutic agents from the beginning of therapy, and in the case of acquired resistance, initially selected drugs are effective, but after a certain period of time, they develop resistance to drugs. Cells acquire cross-resistance to a wide range of drugs with different cellular targets and structures. Therefore, acquired resistance requires the use of ever-increasing concentrations of drugs, in high doses, waiting for a therapeutic effect, which, however, does not appear. The applied treatment becomes ineffective, harmful and destructive to the entire body.
The cellular mechanisms of MDR are defined by changes in the biochemistry of cancer cells consisting of reduced absorption of drugs, their rapid removal from the cell, changes in molecules that are drug targets and their rapid inactivation [2,3,13,14,15]. Classic transport-based mechanisms are associated with the activity of ABC family proteins containing the ATP-binding domain [2]. They are associated with rapid removal of the drug from the cells. Over the years, scientists around the world have been looking for solutions to the problem of drug resistance. One of the methods is the use of compounds that bind MDR transporters and block their effect. This results in sensitization of cells to the chemotherapeutic agents used. These compounds include pharmacological substances, monoclonal antibodies and immunotoxins [16,17,18]. Many studies have been related to the use of P-gp modulators blocking drug-binding sites within P-glycoprotein. The modulator is used together with a cytostatic drug. Due to the higher affinity or increased concentration achieved in the cell, the compound effectively competes with the drug for access to the transport protein. This leads to its saturation and significantly reduces the outflow of the drug from the cell.
The influence of the PI3K/AKT pathway on the development of multidrug resistance is also described in the literature. The signaling pathway of 3-phosphatidyloinositol and AKT protein kinase plays an important role in the development of MDR in various cancers, e.g., breast cancer, lung cancer, leukemia, ovarian cancer and melanoma [19,20,21]. The development of MDR may be related to the PI3K/AKT signaling pathway through activation of the NF-κB protein. NF-κB proteins in their active form function as regulatory transcription proteins. In the process of carcinogenesis, due to abnormal, constant activation of the NF-κB pathway, there is abnormal control of the expression of genes encoding proteins that play an important role in many processes at the cellular level, such as proliferation, differentiation, apoptosis and angiogenesis. Increased NF-κB transcriptional activity has a stimulating effect on the process of cancer cell proliferation by facilitating the transition of cells from the G1 phase to the S phase of the cell cycle as a result of transcription stimulation, among others, cyclin D1. Abnormal activation of the PI3K/AKT/NF-κB pathway also regulates P-gp expression, contributing to the development of MDR [19].
Metformin, a biguanide derivative, according to registration indications, is mainly used for the treatment of type 2 diabetes and for the prevention of various metabolic diseases [22,23]. Mechanism of action of this drug is primarily based on reducing the absorption of sugars in the intestines, inhibiting gluconeogenesis and glycogenolysis in the liver and increasing the sensitivity of cells to insulin (skeletal muscle, heart, liver and adipose tissue) without affecting its production. Molecularly, metformin inhibits respiration in the mitochondria at the level I complex of the respiratory chain [4,24]. The result is a shift in the energy balance of cells that increases AMP kinase activity. Many studies confirm that metformin is a substrate for cationic transporters such as OCT1 (SLC22A1), OCT2 (SLC22A2), OCT3 (SLC22A3), MATE1 (SLC47A1), MATE2 (SLC47A2), PMAT (SLC29A4) and OCTN1 (SLC22A4) [25].
In addition to the hypoglycemic effect, more and more attention is being paid to the beneficial effects of metformin in cancer therapy. The effect of metformin is largely attributed to its ability to modulate the course of the cell cycle, apoptosis, autophagy and inflammatory processes. Attention is also drawn to the possibility of acting on oxidative stress and epigenetic regulation. At the molecular level, the anticancer effect of metformin may be due to the activation of AMP kinase, which inhibits the mammalian target of rapamycin (mTOR). The protective effect independent of AMPK, in turn, is the effect on inflammatory pathways, insulin-like growth factor-1 or leptin. Attention is also drawn to the inhibition of the growth and proliferation of cancer stem cells [4,5,8,26,27,28]. There have also been reports of a beneficial effect of metformin in combination with anticancer drugs, especially in relation to cells resistant to cytostatics [29,30,31,32,33,34].
In the presented study, the effect of metformin on the occurrence of multidrug resistance of breast cancer cells MCF-7 and MCF-7/DX (a line resistant to cytostatics, including doxorubicin) was evaluated. Cell viability in cultures was estimated on the basis of the results of the WST-1 test for the presence of live, metabolically active cells (Figure 1a) and the LDH test for the detection of dead cells with damaged membranes in cell cultures, which release the cytosolic enzyme lactate dehydrogenase into the medium (Figure 1b). The toxic effect of metformin alone on MCF-7 cells was demonstrated only at concentrations above 50 mM and the toxic effect of doxorubicin dependent on its concentration in the medium. Enhancement of the cell toxic effect of doxorubicin was obtained in the presence of metformin (both 12.5 mM and 50 mM). The results of WST-1 obtained of MCF-7/DX cells under the same conditions as for MCF-7 cells show the following: lower sensitivity of MCF-7/DX cells to metformin (the highest decrease in absorbance at a concentration of 100 mM) and doxorubicin (visible decrease metabolic activity of cells only at the concentration of 50 and 100 µM) and a decrease in absorbance after the use of a mixture of doxorubicin and metformin (both after using a 12.5 mM and 50 mM solution, which itself has a slight effect on the viability of MCF-7/DX). However, when dosing metformin in vitro, it should be borne in mind that supraphysiological doses may produce off-target effects that do not reflect in vivo events. Concentrations of 0.1 mM to 100 mM are typically used in vitro studies of metformin effects; for comparison, in vivo concentrations of metformin in human serum at a mean oral daily dose of 1500 mg are 2–38 μM (steady state ranges are 15.5μM) [35,36,37]. In this study, the effect of metformin on increasing the sensitivity of MCF-7 and MCF-7/DX cells to doxorubicin was evaluated on the basis of the results of the MDR test (Sigma-Aldrich) which is recommended as screening tests for MDR pump inhibitors or for identifying cell lines with high MDR activity (Figure 1c). The fluorescence values obtained in the study for cells of the MCF-7 and MCF-7/DX lines exposed to metformin indicate an increased accumulation of the dye in the cells, especially visible in the case of the MCF-7/DX line. On the basis of the structure of metformin, the most important molecular targets for this molecule were analyzed (using the SwissTargetPrediction program) (Figure 2 and Table 1).
The results shown in Table 1 and Figure 2 do not indicate binding to ABC transport proteins. The main target here are carbonic anhydrases, oxidoreductases, nitric oxide synthases and family A G protein-coupled receptors. However, there have been reports of the possibility of affecting the synthesis of MDR-1 and BCRP proteins (through AMPK-independent mechanisms). It has been proven that in the case of MCF-7 cells, metformin can reduce the amount of proteins in MDR-1, BCRP, HIF1α, p53S392phos (compared to total p53) and S6KS411phos (compared to total S6K), and even the number of Erα receptors [35]. Researchers in Brazil have shown that the effect of metformin on MCF-7 resistance is related to oxidative stress. Microarray analyses showed that doxorubicin-resistant cells alter the expression of genes involved in oxidative stress (OS) and the TGF-β pathway. Metformin increases sensitivity to DOX-induced OS; it lowers the concentration of nitric oxide, nuclear NF-kB and Nrf2 and increases nuclear p53. An analysis of the IFN-α signaling pathway has shown that metformin may increase sensitivity to apoptosis [38].

4. Materials and Methods

4.1. Cell Cultures

This research was carried out on cultures of breast cancer cells from a metastatic focus (pleural effusion), which have been bought from the ATCC. Acquired lines are MCF-7 line human-breast-adenocarcinoma cells sensitive to cytostatics and MCF-7/DX human-breast-adenocarcinoma subline cells resistant to cytostatics. The loss of sensitivity to doxorubicin (Sigma-Aldrich) of MCF-7/DX cells was confirmed by the Multidrug Resistance Assay Kit (Sigma-Aldrich).

4.2. Evaluation of the Effect of Metformin on the Sensitivity of Cells to Doxorubicin

The cells were exposed to doxorubicin (Sigma-Aldrich) at a concentration of 1.56–100 µM and metformin (Sigma-Aldrich) at a concentration of 1.56–100 mM and a mixture of doxorubicin at a concentration of 1.56–100 µM with metformin at a concentration of 12.5 mM or 50 mM. After 72 h of incubation (37 °C, 5% CO2), cell viability in cultures was evaluated, and a MDR transporter activity test was performed.

4.3. Cell Viability

After 72 h of incubation with drugs, the WST-1 (Roche Diagnostics, Mannheim, Germany) test for cell viability and the LDH (Roche Diagnostics) test for metformin and doxorubicin cytotoxicity were performed.

4.3.1. WST1 Test (Roche Diagnostics)

A colorimetric assay was used to determine the relative number of viable cells in cultures. WST-1 (tetrazolium salt) is converted by viable, metabolically active cells to soluble formazan. The amount of formazan formed directly correlates with the number of metabolically active cells in the culture. Absorbance was measured at λ = 450 nm and λ = 600 nm as reference wavelength. A UVM340 microplate reader Asys-Hitech GmbH UVM340 (Eugendorf, Austria) was used for absorbance measurements.

4.3.2. LDH Test (Roche Diagnostics)

A colorimetric relative dead-cell assay based on the measurement of lactate dehydrogenase (LDH) activity released from the cytosol of damaged cells into the culture medium. Measurements of absorbance at λ = 450 nm and λ = 600 nm were used as the reference wavelength. A UVM340 microplate reader Asys-Hitech GmbH UVM340 (Eugendorf, Austria) was used for absorbance measurements.

4.4. MDR Test (Sigma-Aldrich)

The kit uses a hydrophobic fluorescent dye molecule to assess MDR activity in cells. The dye quickly penetrates cell membranes, which increases the fluorescence intensity (λex = 490/λem = 525 nm). In drug-resistant cells with MDR transporters, the dye is quickly excreted outside, which reduces the fluorescence intensity. The test is intended for the screening of MDR pump inhibitors or for the identification of cell lines with high MDR activity. Fluorescence intensity was measured at λex = 490/λem = 525 nm using a Triad LT Multimode Detector (Dynex Technologies, Chantilly, VA, USA).

4.5. Prediction of Potential Molecular Targets of Metformin

The possible interactions of metformin with various molecular targets were simulated using the SwissTargetPrediction program [39]. SwissTargetPrediction is a program for predicting macromolecular targets (human and animal proteins) of small molecules. It allows one to predict the molecular mechanisms of action of such a molecule on cells. SwissTargetPrediction is based on the so-called “principle of similarity”, which generally states that two similar molecules have similar properties. SwissTargetPrediction compares particles to 370,000 other known particles.

4.6. Statistical Analysis

Data distribution for each of trials met the requirements of normal distribution (assessed with Wilk–Shapiro test), which gave the basis for a statistical analysis conducted with use of parametric tests. The control group was compared with seven tested groups using Dunnett’s test, after prior confirmation (with an F-test in a variance analysis) of statistically significant differences in the analyzed means. Assumptions of variance homogeneity were checked with use of Levene’s test and Brown–Forsythe’s test. The data were presented as charts with the arithmetic mean for each sample and the corresponding standard deviations. All the tests were performed with a significance level of α = 0.05, using Statistica version 13.3 software.

5. Conclusions

The results obtained in this study indicate that metformin in combination with doxorubicin increases the sensitivity of cancer cells to cytostatics. It has a beneficial effect on eliminating the phenomenon of drug resistance of breast cancer cells. The effect is already visible at concentrations above 12.5 mM.
Based on the results obtained in this work and the descriptions of the effects of similar studies appearing in publications, it can be concluded that metformin is a promising tool in preventing and combating chemoresistance in cancer patients.

Author Contributions

Conceptualization, J.P.-C. and M.L.; methodology, J.P.-C. and M.L.; software, J.P.-C. and M.L.; validation, J.P.-C.; formal analysis, J.P.-C.; investigation, J.P.-C. and L.Ż.; resources, M.L.; data curation, J.P.-C.; writing—original draft preparation, J.P.-C. and L.Ż.; writing—review and editing, M.L.; visualization, J.P.-C. and L.Ż.; supervision, M.L.; project administration, M.L.; funding acquisition, M.L. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by Medical University of Silesia in Katowice, Poland (project number: PCN-1-092/K/1/F).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Any unpublished raw data associated with this research are available by contacting the corresponding author J.P.

Acknowledgments

This work was supported by Medical University of Silesia in Katowice, Poland.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Li, Y.; Wang, Z.; Ajani, J.A.; Song, S. Drug resistance and cancer stem cells. Cell Commun. Signal. 2021, 19, 19. [Google Scholar] [CrossRef] [PubMed]
  2. Choi, Y.H.; Yu, A.M. ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr. Pharm. Des. 2014, 20, 793–807. [Google Scholar] [CrossRef] [PubMed]
  3. Bukowski, K.; Kciuk, M.; Kontek, R. Mechanisms of multidrug resistance in cancer chemotherapy. Int. J. Mol. Sci. 2020, 21, 3233. [Google Scholar] [CrossRef] [PubMed]
  4. LaMoia, T.E.; Shulman, G.I. Cellular and molecular mechanisms of metformin action. Endocr. Rev. 2021, 42, 77–96. [Google Scholar] [CrossRef] [PubMed]
  5. Cwynar-Zając, Ł. Metformin—A new approach. Pediatr. Endocrinol. Diabetes Metab. 2021, 27, 134–140. [Google Scholar] [CrossRef] [PubMed]
  6. Thakur, S.; Daley, B.; Klubo-Gwiezdzinska, J. The role of an anti-diabetic drug metformin in the treatment of endocrine tumors. J. Mol. Endocrinol. 2019, 63, R17–R35. [Google Scholar] [CrossRef] [PubMed]
  7. Almaimani, R.A.; Aslam, A.; Ahmad, J.; El-Readi, M.Z.; El-Boshy, M.E.; Abdelghany, A.H.; Idris, S.; Alhadrami, M.; Althubiti, M.; Almasmoum, H.; et al. In vivo and iv vitro enhanced tumoricidal effects of metformin, active vitamin D3, and 5-fluorouracil triple therapy against colon cancer by modulating the PI3K/Akt/PTEN/mTOR network. Cancers 2022, 14, 1538. [Google Scholar] [CrossRef]
  8. Chen, Y.H.; Wu, J.X.; Yang, S.F.; Chen, M.L.; Chen, T.H.; Hsiao, Y.H. Metformin potentiates the anticancer effect of everolimus on cervical cancer in vitro and in vivo. Cancers 2021, 13, 4612. [Google Scholar] [CrossRef] [PubMed]
  9. Chen, Y.H.; Wang, P.H.; Chen, P.N.; Yang, S.F.; Hsiao, Y.H. Molecular and cellular mechanisms of metformin in cervical cancer. Cancers 2021, 13, 2545. [Google Scholar] [CrossRef]
  10. Roshan, M.H.; Shing, Y.K.; Pace, N.P. Metformin as an adjuvant in breast cancer treatment. SAGE Open Med. 2019, 7, 2050312119865114. [Google Scholar] [CrossRef]
  11. Farahi, A.; Abedini, M.R.; Javdani, H.; Arzi, L.; Chamani, E.; Farhoudi, R.; Talebloo, N.; Hoshyar, R. Crocin and metformin suppress metastatic breast cancer progression via VEGF and MMP9 downregulations: In vitro and in vivo studies. Mol. Cell. Biochem. 2021, 476, 3341–3351. [Google Scholar] [CrossRef] [PubMed]
  12. Wu, H.; Huang, D.; Zhou, H.; Sima, X.; Wu, Z.; Sun, Y.; Wang, L.; Ruan, Y.; Wu, Q.; Wu, F.; et al. Metformin: A promising drug for human cancers (review). Oncol. Lett. 2022, 24, 204. [Google Scholar] [CrossRef] [PubMed]
  13. Tsuruo, T.; Naito, M.; Tomida, A.; Fujita, N.; Mashima, T.; Sakamoto, H.; Haga, N. Molecular targeting therapy of cancer: Drug resistance, apoptosis and survival signal. Cancer Sci. 2003, 94, 15–21. [Google Scholar] [CrossRef]
  14. Vaidya, F.U.; Sufiyan Chhipa, A.; Mishra, V.; Gupta, V.K.; Rawat, S.G.; Kumar, A.; Pathak, C. Molecular and cellular paradigms of multidrug resistance in cancer. Cancer Rep. 2022, 5, e1291. [Google Scholar] [CrossRef]
  15. Zhong, T.; Zhang, W.; Guo, H.; Pan, X.; Chen, X.; He, Q.; Yang, B.; Ding, L. The regulatory and modulatory roles of TRP family channels in malignant tumors and relevant therapeutic strategies. Acta Pharm. Sin. B 2021, 12, 1761–1780. [Google Scholar] [CrossRef] [PubMed]
  16. Nussinov, R.; Tsai, C.J.; Jang, H. Anticancer drug resistance: An update and perspective. Drug Resist. Updates 2021, 59, 100796. [Google Scholar] [CrossRef]
  17. Haider, T.; Pandey, V.; Banjare, N.; Gupta, P.N.; Soni, V. Drug resistance in cancer: Mechanisms and tackling strategies. Pharmacol. Rep. 2020, 72, 1125–1151. [Google Scholar] [CrossRef]
  18. Mir, S.A.; Hamid, L.; Bader, G.N.; Shoaib, A.; Rahamathulla, M.; Alshahrani, M.Y.; Alam, P.; Shakeel, F. Role of nanotechnology in overcoming the multidrug resistance in cancer therapy: A review. Molecules 2022, 27, 6608. [Google Scholar] [CrossRef]
  19. Liu, R.; Chen, Y.; Liu, G.; Li, C.; Song, Y.; Cao, Z.; Li, W.; Hu, J.; Lu, C.; Liu, Y. PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis. 2020, 11, 797. [Google Scholar] [CrossRef]
  20. Kaboli, P.J.; Imani, S.; Jomhori, M.; Ling, K.H. Chemoresistance in breast cancer: PI3K/Akt pathway inhibitors vs the current chemotherapy. Am. J. Cancer Res. 2021, 11, 5155–5183. [Google Scholar]
  21. Rascio, F.; Spadaccino, F.; Rocchetti, M.T.; Castellano, G.; Stallone, G.; Netti, G.S.; Ranieri, E. The pathogenic role of PI3K/AKT pathway in cancer onset and drug resistance: An updated review. Cancers 2021, 13, 3949. [Google Scholar] [CrossRef] [PubMed]
  22. Singh, A.K.; Singh, R.; Chakraborty, P.P. Diabetes monotherapies versus metformin-based combination therapy for the treatment of type 2 diabetes. Int. J. Gen. Med. 2021, 14, 3833–3848. [Google Scholar] [CrossRef]
  23. Baker, C.; Retzik-Stahr, C.; Singh, V.; Plomondon, R.; Anderson, V.; Rasouli, N. Should metformin remain the first-line therapy for treatment of type 2 diabetes? Ther. Adv. Endocrinol. Metab. 2021, 12, 2042018820980225. [Google Scholar] [CrossRef] [PubMed]
  24. Vial, G.; Detaille, D.; Guigas, B. Role of mitochondria in the mechanism(s) of action of metformin. Front. Endocrinol. 2019, 10, 294. [Google Scholar] [CrossRef]
  25. Kölz, C.; Schaeffeler, E.; Schwab, M.; Nies, A.T. Genetic and epigenetic regulation of organic cation transporters. Handb. Exp. Pharmacol. 2021, 266, 81–100. [Google Scholar] [CrossRef]
  26. Kim, Y.C.; Guan, K.L. mTOR: A pharmacologic target for autophagy regulation. J. Clin. Investig. 2015, 125, 25–32. [Google Scholar] [CrossRef]
  27. Saini, N.; Yang, X. Metformin as an anti-cancer agent: Actions and mechanisms targeting cancer stem cells. Acta Biochim. Biophys. Sin. 2018, 50, 133–143. [Google Scholar] [CrossRef]
  28. Mallik, R.; Chowdhury, T.A. Metformin in cancer. Diabetes Res. Clin. Pract. 2018, 143, 409–419. [Google Scholar] [CrossRef] [PubMed]
  29. Jeong, Y.S.; Lam, T.G.; Jeong, S.; Ahn, S.G. Metformin derivative HL156A reverses multidrug resistance by inhibiting HOXC6/ERK1/2 signaling in multidrug-resistant human cancer cells. Pharmaceuticals 2020, 13, 218. [Google Scholar] [CrossRef]
  30. Shafiei-Irannejad, V.; Samadi, N.; Salehi, R.; Yousefi, B.; Rahimi, M.; Akbarzadeh, A.; Zarghami, N. Reversion of multidrug resistance by co-encapsulation of doxorubicin and metformin in poly(lactide-co-glycolide)-d-α-tocopheryl polyethylene glycol 1000 succinate nanoparticles. Pharm. Res. 2018, 35, 119. [Google Scholar] [CrossRef]
  31. Tang, Z.; Tang, N.; Jiang, S.; Bai, Y.; Guan, C.; Zhang, W.; Fan, S.; Huang, Y.; Lin, H.; Ying, Y. The chemosensitizing role of metformin in anti-cancer therapy. Anticancer Agents Med. Chem. 2021, 21, 949–962. [Google Scholar] [CrossRef] [PubMed]
  32. Zhang, H.; Yu, J.; Ma, L.; Zhao, Y.; Xu, S.; Shi, J.; Qian, K.; Gu, M.; Tan, H.; Xu, L.; et al. Reversing multi-drug resistance by polymeric metformin to enhance antitumor efficacy of chemotherapy. Int. J. Pharm. 2022, 624, 121931. [Google Scholar] [CrossRef] [PubMed]
  33. Sun, Y.; Chen, X.; Zhou, Y.; Qiu, S.; Wu, Y.; Xie, M.; Zhu, G.; Liang, S.; Li, H.; Zhou, D.; et al. Metformin reverses the drug resistance of cisplatin in irradiated CNE-1 human nasopharyngeal carcinoma cells through PECAM-1 mediated MRPs down-regulation. Int. J. Med. Sci. 2020, 17, 2416–2426. [Google Scholar] [CrossRef] [PubMed]
  34. Xiao, Y.; Wang, S.; Zong, Q.; Yin, Z. Co-delivery of metformin and paclitaxel via folate-modified pH-sensitive micelles for enhanced anti-tumor efficacy. AAPS Pharm. Sci. Tech. 2018, 19, 2395–2406. [Google Scholar] [CrossRef] [PubMed]
  35. Davies, G.; Lobanova, L.; Dawicki, W.; Groot, G.; Gordon, J.R.; Bowen, M.; Harkness, T.; Arnason, T. Metformin inhibits the development, and promotes the resensitization, of treatment-resistant breast cancer. PLoS ONE 2017, 12, e0187191. [Google Scholar] [CrossRef] [PubMed]
  36. Frid, A.; Sterner, G.N.; Londahl, M.; Wiklander, C.; Cato, A.; Vinge, E.; Andersson, A. Novel assay of metformin levels in patients with type 2 diabetes and varying levels of renal function: Clinical recommendations. Diabetes Care 2010, 33, 1291–1293. [Google Scholar] [CrossRef]
  37. (FDA) Food and Drug Administration; US Department of Health and Human Services. Metformin Hydrochloride Tablets: Fda.gov Accessed 30 May 2017. Available online: www.fda.gov/ohrms/dockets/dailys/02/May02/053102/800471e6.pdf (accessed on 3 December 2022).
  38. Marinello, P.C.; Panis, C.; Silva, T.N.X.; Binato, R.; Abdelhay, E.; Rodrigues, J.A.; Mencalha, A.L.; Lopes, N.M.D.; Luiz, R.C.; Cecchini, R.; et al. Metformin prevention of doxorubicin resistance in MCF-7 and MDA-MB-231 involves oxidative stress generation and modulation of cell adaptation genes. Sci. Rep. 2019, 9, 5864. [Google Scholar] [CrossRef]
  39. Swiss Institute of Bioinformatics. Available online: http://swisstargetprediction.ch (accessed on 3 December 2022).
Molecules 29 03531 g001aMolecules 29 03531 g001b
Figure 1. (a) The effect of different doses of metformin (1.56–100 mM), doxorubicin (1.56–100 µM) and mixture of doxorubicin (1.56–100 µM) with metformin (12.5 mM and 50 mM) on the metabolic activity of MCF-7 and MCF-7/DX cells (WST-1 assay). (b) The cytotoxicity effect of different doses of metformin (1.56–100 mM), doxorubicin (1.56–100 µM) and mixture of doxorubicin (1.56–100 µM) with metformin (12.5 mM and 50 mM) in the MCF-7 and MCF-7/DX in vitro cultures (LDH assay). (c) The effectiveness of different doses of metformin (1.56–100 mM) in overcoming the resistance of the MCF-7 and MCF-7/DX cells to doxorubicin (MDR assay). Statistical significance is set to p ≤ 0.05 (*).
Figure 1. (a) The effect of different doses of metformin (1.56–100 mM), doxorubicin (1.56–100 µM) and mixture of doxorubicin (1.56–100 µM) with metformin (12.5 mM and 50 mM) on the metabolic activity of MCF-7 and MCF-7/DX cells (WST-1 assay). (b) The cytotoxicity effect of different doses of metformin (1.56–100 mM), doxorubicin (1.56–100 µM) and mixture of doxorubicin (1.56–100 µM) with metformin (12.5 mM and 50 mM) in the MCF-7 and MCF-7/DX in vitro cultures (LDH assay). (c) The effectiveness of different doses of metformin (1.56–100 mM) in overcoming the resistance of the MCF-7 and MCF-7/DX cells to doxorubicin (MDR assay). Statistical significance is set to p ≤ 0.05 (*).
Molecules 29 03531 g001aMolecules 29 03531 g001b
Molecules 29 03531 g002
Figure 2. Diagram showing molecular targets for metformin determined from drug structure using the SwissTargetPrediction program.
Figure 2. Diagram showing molecular targets for metformin determined from drug structure using the SwissTargetPrediction program.
Molecules 29 03531 g002
Table 1. Molecular targets for metformin determined from drug structure using the SwissTargetPrediction program.
Table 1. Molecular targets for metformin determined from drug structure using the SwissTargetPrediction program.
Query MoleculeMolecules 29 03531 i001
TargetTarget ClassCommon Name
Adrenergic receptor alpha-2Family A G protein-coupled receptorADRA2C
Alpha-1a adrenergic receptorFamily A G protein-coupled receptorADRA1A
Alpha-1b adrenergic receptorFamily A G protein-coupled receptorADRA1B
Alpha-1d adrenergic receptorFamily A G protein-coupled receptorADRA1D
Alpha-2a adrenergic receptorFamily A G protein-coupled receptorADRA2A
Alpha-2b adrenergic receptorFamily A G protein-coupled receptorADRA2B
Amine oxidase, copper containingEnzymeAOC3
Carbonic anhydrase ILyaseCA1
Carbonic anhydrase IILyaseCA2
Carbonic anhydrase IXLyaseCA9
Dihydrofolate reductaseOxidoreductaseDHFR
Histamine H3 receptorFamily A G protein-coupled receptorHRH3
Histamine H4 receptorFamily A G protein-coupled receptorHRH4
Indoleamine 2,3-dioxygenaseEnzymeIDO1
Integrin alpha-V/beta-3Membrane receptorITGAV ITGB3
NischarinOther cytosolic proteinNISCH
Nitric oxide synthase, inducibleEnzymeNOS2
Nitric oxide synthase, brainEnzymeNOS1
Nitric oxide synthase, endothelialEnzymeNOS3
S-100 protein beta chainOther cytosolic proteinS100B
Serotonin 1a (5-HT1a) receptorFamily A G protein-coupled receptorHTR1A
Serotonin 1b (5-HT1b) receptorFamily A G protein-coupled receptorHTR1B
Serotonin 1d (5-HT1d) receptorFamily A G protein-coupled receptorHTR1D
Serotonin 2a (5-HT2a) receptorFamily A G protein-coupled receptorHTR2A
Serotonin 2b (5-HT2b) receptorFamily A G protein-coupled receptorHTR2B
Serotonin 2c (5-HT2c) receptorFamily A G protein-coupled receptorHTR2C
Serotonin 3a (5-HT3a) receptorLigand-gated ion channelHTR3A
Serotonin 5a (5-HT5a) receptorFamily A G protein-coupled receptorHTR5A
Serotonin 6 (5-HT6) receptorFamily A G protein-coupled receptorHTR6
Serotonin 7 (5-HT7) receptorFamily A G protein-coupled receptorHTR7
ThrombinProteaseF2
Thrombin and coagulation factor XProteaseF10
Urokinase-type plasminogen activatorProteasePLAU
ADRA2C—adrenergic receptor alpha-2, ADRA1A—alpha-1a adrenergic receptor, ADRA1B—alpha-1b adrenergic receptor, ADRA1D—alpha-1d adrenergic receptor, ADRA2A—alpha-2a adrenergic receptor, ADRA2B—alpha-2b adrenergic receptor, AOC3—amine oxidase, copper containing, CA1—carbonic anhydrase I, CA2—carbonic anhydrase II, CA9—carbonic anhydrase IX, DHFR—dihydrofolate reductase, HRH3—histamine H3 receptor, HRH4—histamine H4 receptor, IDO1—indoleamine 2,3-dioxygenase, NISCH—nischarin, NOS2—nitric oxide synthase, inducible, NOS1—nitric oxide synthase, brain, NOS3—nitric oxide synthase, endothelial, S100B—S-100 protein beta chain, HTR1A—serotonin 1a (5-HT1a) receptor, HTR1B—serotonin 1b (5-HT1b) receptor, HTR1D—serotonin 1d (5-HT1d) receptor, HTR2A—serotonin 2a (5-HT2a) receptor, HTR2B—serotonin 2b (5-HT2b) receptor, HTR2C—serotonin 2c (5-HT2c) receptor, HTR3A—serotonin 3a (5-HT3a) receptor, HTR5A—serotonin 5a (5-HT5a) receptor, HTR6—serotonin 6 (5-HT6) receptor, HTR7—serotonin 7 (5-HT7) receptor, F2—thrombin, F10—thrombin and coagulation factor X, PLAU—urokinase-type plasminogen activator.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Płonka-Czerw, J.; Żyrek, L.; Latocha, M. Changes in the Sensitivity of MCF-7 and MCF-7/DX Breast Cancer Cells to Cytostatic in the Presence of Metformin. Molecules 2024, 29, 3531. https://doi.org/10.3390/molecules29153531

AMA Style

Płonka-Czerw J, Żyrek L, Latocha M. Changes in the Sensitivity of MCF-7 and MCF-7/DX Breast Cancer Cells to Cytostatic in the Presence of Metformin. Molecules. 2024; 29(15):3531. https://doi.org/10.3390/molecules29153531

Chicago/Turabian Style

Płonka-Czerw, Justyna, Luiza Żyrek, and Małgorzata Latocha. 2024. "Changes in the Sensitivity of MCF-7 and MCF-7/DX Breast Cancer Cells to Cytostatic in the Presence of Metformin" Molecules 29, no. 15: 3531. https://doi.org/10.3390/molecules29153531

APA Style

Płonka-Czerw, J., Żyrek, L., & Latocha, M. (2024). Changes in the Sensitivity of MCF-7 and MCF-7/DX Breast Cancer Cells to Cytostatic in the Presence of Metformin. Molecules, 29(15), 3531. https://doi.org/10.3390/molecules29153531

Article Metrics

Back to TopTop